header
Local cover image
Local cover image
Image from OpenLibrary

Hepatic arterial chemoperfusion in treatment of advanced hepatocellular carcinoma with portal vein thrombosis / Rana Salah Moawad Abdelhady ; Supervised Iman Mohammed Hamza , Hend Ibrahim Hassan Shousha , Ahmed Hosni Kamal

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Rana Salah Moawad Abdelhady , 2019Description: 117 P . : charts , facsmilies ; 25cmOther title:
  • الحقن الكيميائى للشريان الكبدى لمرضى سرطان الكبد المتقدم مع التجلط السرطانى للوريد البابى [Added title page title]
Subject(s): Online resources: Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine Summary: orafenib, the multi-kinase inhibitor, is the standard of care for patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) according to EASL guidelines. Other guidelines as the Japanese and Korean recommended hepatic arterial infusion chemotherapy (HAIC) as first line for patients with PVTT followed by Sorafenib as second line and keeping Sorafenib as first line for advanced HCC without PVTT. Aim of work: The aim of this study is to describe the treatment efficacy and survival benefits of HAIC for patients with advanced HCC and PVTT, BCLC-C with compensated cirrhosis (Child-Pugh A) in comparison with Sorafenib as standard of care therapy for such patients versus Best Supportive Care (BSC). Patients and methods: This study included ninety one patients with advanced HCC and PVTT who were recruited from multidisciplinary HCC clinic, Kasr-Alainy, in the period fromApril 2016 till June 2017.Patients were divided into three groups: Group 1: 20 treated with HAIC, The patients received arterial infusion of chemotherapeutic agents in the form of 50 mg Adriamycin and 50 mg Cisplatin.Group 2:42 patients were treated with BSC and Group 3: 29 patients were treated with Sorafenib. The dose of sorafenib was adjusted according to adverse events. Patients were followed up for assessment and comparison of treatment outcome by modified RECIST criteriaand survival
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.33.M.Sc.2019.Ra.H (Browse shelf(Opens below)) Not for loan 01010110081802000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.33.M.Sc.2019.Ra.H (Browse shelf(Opens below)) 81802.CD Not for loan 01020110081802000
Browsing المكتبة المركزبة الجديدة - جامعة القاهرة shelves Close shelf browser (Hides shelf browser)
No cover image available
No cover image available
No cover image available
No cover image available
No cover image available
No cover image available
No cover image available
Cai01.11.33.M.Sc.2019.Mo.A Assessment of urinary Ý 2microglobulin as a sensitive marker for renal tubular dysfunction in chronic hepatitis b patients receiving tenofovir therapy / Cai01.11.33.M.Sc.2019.Ra.A Assessment of treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate (antimonial compounds) with or without intramuscular stibogluconate in a group of Egyptian patients / Cai01.11.33.M.Sc.2019.Ra.A Assessment of treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate (antimonial compounds) with or without intramuscular stibogluconate in a group of Egyptian patients / Cai01.11.33.M.Sc.2019.Ra.H Hepatic arterial chemoperfusion in treatment of advanced hepatocellular carcinoma with portal vein thrombosis / Cai01.11.33.M.Sc.2019.Ra.H Hepatic arterial chemoperfusion in treatment of advanced hepatocellular carcinoma with portal vein thrombosis / Cai01.11.33.M.Sc.2019.Yo.S The significance of hsa-miR-222-3p, hsa-miR-21-5p, hsa-miR-122-5p in HCV related hepatocellular carcinoma and its relation to directly acting antivirals among Egyptian patients / Cai01.11.33.M.Sc.2019.Yo.S The significance of hsa-miR-222-3p, hsa-miR-21-5p, hsa-miR-122-5p in HCV related hepatocellular carcinoma and its relation to directly acting antivirals among Egyptian patients /

Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine

orafenib, the multi-kinase inhibitor, is the standard of care for patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) according to EASL guidelines. Other guidelines as the Japanese and Korean recommended hepatic arterial infusion chemotherapy (HAIC) as first line for patients with PVTT followed by Sorafenib as second line and keeping Sorafenib as first line for advanced HCC without PVTT. Aim of work: The aim of this study is to describe the treatment efficacy and survival benefits of HAIC for patients with advanced HCC and PVTT, BCLC-C with compensated cirrhosis (Child-Pugh A) in comparison with Sorafenib as standard of care therapy for such patients versus Best Supportive Care (BSC). Patients and methods: This study included ninety one patients with advanced HCC and PVTT who were recruited from multidisciplinary HCC clinic, Kasr-Alainy, in the period fromApril 2016 till June 2017.Patients were divided into three groups: Group 1: 20 treated with HAIC, The patients received arterial infusion of chemotherapeutic agents in the form of 50 mg Adriamycin and 50 mg Cisplatin.Group 2:42 patients were treated with BSC and Group 3: 29 patients were treated with Sorafenib. The dose of sorafenib was adjusted according to adverse events. Patients were followed up for assessment and comparison of treatment outcome by modified RECIST criteriaand survival

Issued also as CD

There are no comments on this title.

to post a comment.

Click on an image to view it in the image viewer

Local cover image